Living Well with Follicular Lymphoma: Understanding Watch & Wait (Active Monitoring)
This free webinar was open to all and featured expert discussion and lived experience on the topic of Watch & Wait in follicular lymphoma.
Nicolas’s Story
My name is Nicolas, and I am from Omaha, Nebraska in the United States. I am at stage 3 FL and was diagnosed in 2024. I am a Union Ironworker, and I live with my girlfriend and our six-week-old baby girl.
Finding a Clinical Trial: Dr. Mitchell Smith, FLF Chief Medical Officer, Provides Expert Advice on Your Important Questions
In this Q&A, Dr. Mitchell Smith dives into common questions on how to find and join a clinical trial, helping you navigate the complexities for follicular lymphoma patients.
Transformation vs Progression: What Patients Need To Know
Understanding the difference can help you feel more in control, ask the right questions at appointments, and better navigate what may come next.
From Strength to Strength: How Our Community Shapes the FLF Webinars
Built on the voices of patients, guided by expert insight, and shaped by ongoing feedback, here’s how the program continues to grow, with your help.
The Role of Nutrition in Follicular Lymphoma
I believe that nutrition is an essential part of cancer care, not an alternative to medical treatment but a crucial complement to it.
Highlights from our satellite symposium “Charting our Progress Towards a Cure”
At the recent 18th International Conference on Malignant Lymphoma (ICML), the FLF shone a spotlight on follicular lymphoma by hosting our very own satellite symposium for the second time, titled: “Charting our Progress Towards a Cure”. Read more to find out the key takeaways and highlights from the symposium.
Lori’s story
My name is Lori and I’m from Alabama, USA. I have stage 3A FL an was diagnosed last year, 2024. Once you are diagnosed and have a clear plan, you will get in a fight mode. It’s important to be aware that for some people the full realization of what you’ve been through may not hit you until after treatment is over.
Webinar: Improving Patient Outcomes via Novel Bispecific Antibody Treatment Options for B-Cell non-Hodgkin Lymphomas
Please watch our informative webinar around Improving Patient Outcomes via Novel Bispecific Antibody Treat Options for B-Cell non-Hodgkin Lymphomas
Tafasitamab Treatment Option Approved for Relapsed or Refractory Follicular Lymphoma in US
In June 2025, the U.S. Food and Drug Administration (FDA) approved a new combination treatment option for adults with relapsed or refractory follicular lymphoma (FL).
This combination includes tafasitamab (also known as Monjuvi®, developed by Incyte), rituximab, and lenalidomide — and is now available for eligible patients in the United States.